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Abstract
In the past few decades, the increasing socioeconomic burden of acute
diverticulitis (AD) has become evident, and with the growth of the population
age, this significant economic impact will likely continue to rise. Furthermore,
recent evidence showed an increased rate of hospital admissions especially
evident among women and younger individuals. The natural history and
pathophysiology of this clinical condition is still to be fully defined, and efforts
continue to be made in the identification of risk factors and the establishment of
relative preventive strategies. The actual therapeutic strategies aimed to
modulate gut microbiota, such as rifaximin or probiotics, or to reduce mucosal
inflammation, such as mesalazine, present a relatively poor efficacy for both the
prevention of the first AD episode (primary prevention) and its recurrence
(secondary prevention). In the last few years, the main goal achieved has been
in the management of AD in that uncomplicated AD can, to a larger extent, be
managed in an outpatient setting with no or little supportive therapy, a strategy
that will certainly impact on the health costs of this disease. The problem of AD
recurrence remains a topic of debate.
The aim of this review is to present updated evidence on AD epidemiology and
relative open clinical questions and to analyze in detail predisposing and
protective factors with an attempt to integrate their possible modes of action
into the several pathogenic mechanisms that have been suggested to
contribute to this multifactorial disease. A unifying hypothesis dealing with the
colonic luminal and extra-luminal microenvironments separately is provided.
Finally, evidence-based changes in therapeutic management will be
summarized. Because of an ascertained multifactorial pathogenesis of
uncomplicated and complicated AD, it is probable that a single ‘causa prima’
will not be identifiable, and a better stratification of patients could allow one to
pursue tailored therapeutic algorithm strategies.
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Introduction
Colonic diverticula, sac-like herniations of the colonic mucosa 
and submucosa through the muscle layers, represent a common 
gastrointestinal condition in the Western world with a prevalence 
that grows with age, from less than 10% in people younger than 
40 years of age to 50–66% after 80 years of age1,2. While most 
people with colonic diverticula remain asymptomatic, making 
diverticulosis not a disease per se, around 20% of patients 
will develop diverticular disease (DD) when they experience 
abdominal symptoms (i.e. symptomatic uncomplicated DD 
[SUDD]) and 1–4% will develop acute diverticulitis (AD)3. The 
natural history and pathophysiology of this clinical condition are 
still under definition. Clinical scenarios of DD and its natural 
history have been recently summarized4. In the past few decades, 
the increasing socioeconomic burden of DD has become evident, 
and efforts have been made to identify risk factors to establish 
relative preventive strategies and to achieve more standardized 
treatment approaches.
The aim of this review is to present updated evidence on AD 
epidemiology and relative open clinical questions and to analyze 
in detail predisposing and protective factors with the attempt 
to integrate their possible modes of action into the several 
pathogenic mechanisms that have been suggested to contribute 
to this multifactorial disease. Finally, evidence-based changes in 
therapeutic management will be summarized.
The clinical problem and its impact on health costs
AD is an inflammatory process that involves one or more 
colonic diverticula, often associated with pericolonic inflamma-
tion that is classified as uncomplicated or complicated, the latter 
being characterized by the presence of abscesses, fistulas, 
peritonitis, and colonic stenosis. Complications most commonly 
occur with the first episode of AD5. AD clinical classifica-
tion is mainly based on the use of modified Hinchey’s criteria 
derived from contrast-enhanced computerized tomography 
(CT) imaging6 or on the more recent German guidelines7. How-
ever, an important role in AD diagnosis is also covered by 
abdominal ultrasound (US), which, in the hands of experienced 
investigators, can be used as a sensitive and specific diagnostic 
technique, limiting the use of CT after negative or inconclusive 
abdominal US7–10.
Recent epidemiological studies have confirmed the increase 
of hospital admissions for AD in recent years11. A previous 
epidemiological analysis, carried out in the USA in 201212, showed 
that diverticulitis was the third most-common gastrointestinal 
diagnosis from hospital admission and the leading indication 
for elective colon resection, with an increase of 41% from 2000 
and an estimated cost of 2.6 billion dollars per year. A more 
recent analysis showed that the national cost of diverticulitis- 
related emergency department visits in the USA, from 2006 to 
2013, increased by 105%13. Similarly, a recent observational 
analysis based on real-world data from an Italian region 
reported that direct healthcare costs for episodes of diverticulitis 
from 2008–2014 amounted to approximately 11.4 million euros, 
of which 95.5% was for hospitalizations14. With the growth of 
the population age, this significant economic burden is likely to 
continue to rise.
Currently, the increased rate of hospital admissions is espe-
cially evident among women and younger individuals5,15. Gender 
differences are age related in that hospital admissions for AD 
are predominant in men among subjects younger than 45 years 
of age, the opposite being true at older ages11. Besides, even if 
older patients display the highest rate of hospital admissions for 
AD, the increased rate of hospitalization is entirely accounted for 
by the younger cohorts of patients13.
Open clinical questions
Recent randomized controlled trials (RCTs) confirmed, and 
national guidelines recommended, that patients with uncom-
plicated AD are eligible for outpatient treatment without the use 
of systemic antibiotics, which should be used in complicated 
patients instead16–19. This conservative management strategy, if 
adopted, could positively influence the relative economic burden 
on health costs. However, the problem of AD recurrence remains 
a topic of debate.
In a recent retrospective population-based cohort study of 
65,162 patients identified with a first episode of AD, the rate of 
hospital admission for recurrence was 11.2%20, lower than was 
previously reported21. This recurrence rate was greater in 
younger people and women5. Generally, the first episode is 
the most severe, with only 2% of recurrences resulting in a 
complicated case. Surgical treatment does not prevent the risk of 
recurrence, the rate of which is around 15%22,23.
Also, AD seems to predispose patients to developing long-
term chronic nonspecific abdominal symptoms, similar to those 
observed in post-infectious irritable bowel syndrome24, with a 
higher prevalence after severe AD25. The proportion of patients 
that develop chronic abdominal pain after AD seems to be 
influenced by the type of treatment of the first episode, with a 
lower prevalence after elective laparoscopy (11%) compared to 
conservative treatment (39%)26.
As for now, the underlying mechanisms and risk factors that 
contribute to AD and its recurrence still need to be clarified. The 
actual therapeutic strategies aimed to modulate gut microbiota, 
such as rifaximin or probiotics, or to reduce mucosal inflamma-
tion, such as mesalazine, present a relatively poor efficacy for the 
prevention of the first AD episode (primary prevention) and its 
recurrence (secondary prevention) (see later). A definite assess-
ment of AD-predisposing or -protective factors and these relative 
mechanisms could greatly contribute to patients receiving the 
best strategy for prevention, further reducing health costs, and 
improving the management of DD.
Risk factors for acute diverticulitis and relative 
recurrence
The identification of risk factors for AD has been the scope of 
several studies for the past few decades. In the last few years, 
the main concern has been to clarify whether or not factors 
associated with the first episode are also involved in AD 
recurrence27. Predisposing and protective factors for AD are 
summarized in Table 1. Among anthropometric features, obesity 
has been confirmed to be a risk factor for AD by a population- 
based cohort study28 and a recent systematic review and 
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Table 1. Summary of predisposing and protective factors associated with primary and secondary prevention of acute diverticulitis.
Predisposing Protective Need to be confirmed Irrelevant
Anthropometric and anatomic features 
- BMI 
- waist circumference 
- waist–hip ratio 
- pancolic diverticula 
 
Lifestyle  
- smoking 
 
Diet  
- red meat intake 
 
Drugs  
- aspirin 
- NSAIDs 
- corticosteroids 
- opioids
Lifestyle  
- vigorous physical activity 
 
Diet  
- high-fiber intake 
 
Drugs  
- statins 
 
Others  
- increased vitamin D levels
 
- alcohol 
- younger age 
- female gender >50 years old 
- genetic factors 
       •  family history 
       •  TFNSF15 polymorphisms 
       •  LAMB4 variants 
- calcium antagonists 
- comorbidities: 
       •  cardiovascular diseases 
       •  chronic obstructive pulmonary disease 
       •  end-stage renal disease
Diet  
- nuts 
- popcorn 
- corn 
- fine or coarse grains 
- coffee
BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory drugs
meta-analysis of prospective studies29, a risk previously reported 
in men in whom waist-to-hip ratio was also associated with the 
risk of diverticular complications30. As far as smoking is 
concerned, a lifestyle risk factor already known to be associated 
with AD, recent evidence showed that it further represents an 
increased risk of developing complicated AD31,32 and requiring 
surgery33. Red meat intake, particularly of unprocessed meat, 
was identified as the main dietary risk factor for diverticulitis in a 
prospective Health Professionals Follow-Up Study (1986–2012) 
of 46,461 men34.
A systematic review and meta-analysis35 confirmed that non- 
steroidal anti-inflammatory drugs (NSAIDs), which are already 
known to be risk factors for AD36 and perforation37, as well 
as steroids and opioids, presented an increased odds ratio for 
perforation and abscess formation.
Among protective factors, vigorous physical activity, as was 
previously reported38, was confirmed by a recent meta-analysis 
to be inversely related to diverticulitis29 but not by a population- 
based cohort study28. As far as diet is concerned, no recent 
further evidence is available on the lower risk of hospitaliza-
tion for AD with a vegetarian diet and a high intake of dietary 
fibers39,40. Instead, statins, which have already been associated 
with a reduced risk of perforation35,37, have also been recently 
reported to be associated with a reduced risk of emergency 
surgery41. Finally, vitamin D serum levels, which when high 
pre-diagnostically have been associated with a low risk of AD 
among patients with diverticulosis42, have been related to the 
severity of DD endoscopic appearance43.
Some known risk factors still need to be confirmed. Evidence 
regarding alcohol consumption and DD are discordant, with 
some studies showing a positive association44,45 and others not46. 
Regarding drugs, the potential protective effect of calcium 
channel blockers in reducing the rate of diverticular complications 
observed in case-control analyses37,47 needs to be confirmed. 
Also, the recent epidemiological evidence that reports a higher 
prevalence of AD among women older than 50 years of age11,48, 
younger individuals5,11,13, and patients with end-stage renal 
disease49, as well as the association of cardiovascular disease 
and chronic obstructive pulmonary disease with complicated 
DD28,50, needs to be confirmed and explained.
Finally, recent studies corroborate the previous observation 
of a strong familial aggregation both in diverticulosis and in 
diverticular complications, suggesting a role for genetic factors51. 
A relationship has been reported between complicated diverticu-
litis and a single nuclear polymorphism in the TFNSF15 gene, 
a T-cell maturation receptor gene associated with other colonic 
inflammatory diseases52, and between early onset diverticuli-
tis or unrelated sporadic diverticulitis and variants in the laminin 
β4 gene (LAMB4), which codes for constituents of the extra-
cellular matrix that regulate the function of the enteric nervous 
system53.
Of note, even if clinicians frequently advised patients to avoid 
some foods, such as nuts, corn, and popcorn, these are not associ-
ated with an increased risk of diverticulitis54, and the same is true 
for fine or coarse grains28. Regarding the possible role of coffee, a 
previous study did not report any association between coffee use 
and DD44, similar to a recent cross-sectional study that did not 
observe any significant difference between coffee drinking and 
diverticulosis compared to SUDD or previous diverticulitis55.
An assessment of risk factors associated with recurrent AD is on 
its way, even if more studies are required to better target 
secondary prevention. Currently, increased risks of recurrent 
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AD, obtained with a logistic regression model, have been shown 
to be younger age, female sex, smoking, obesity, a Charlson 
comorbidity index score of more than 20, dyslipidemia, and 
first complicated AD20. Other risks of recurrence are primary 
diverticulitis with abscess formation, an inflamed segment of 
more than 5 cm, multiple diverticula, and diverticula throughout 
the colon, with the risk of subsequent diverticulitis more than 
doubled after two earlier episodes of diverticulitis that further 
increases for every episode of recurrence56.
Pathophysiology and possible underlying biological 
mechanisms
A unifying hypothesis to integrate the diverse risk factors and 
their contribution to the pathophysiology of AD has not yet been 
put forward. The current hypothesis asserts that the susceptibil-
ity of diverticula to inflammation is explained by local ischemia, 
retained stool, stercoral mucosal trauma by fecaliths, and 
diverticular wall distension that facilitates microperforations 
and favors bacterial translocation57. Inflammation and infections 
can spread transmurally (peridiverticulitis), ending in different 
types of AD complications. The improvement of the clinical 
outcome of the disease obtained with antibiotics supports an 
involvement of bacteria in most AD complications. A dual 
inflammatory–infective contribution might then be considered 
in AD pathogenesis58,59 with likely different interconnections if 
considering the luminal colonic and the extra-luminal microenvi-
ronments (Figure 1).
The luminal microenvironment is dominated by microbiota 
that has been suggested to play an important role in the 
pathogenesis of the disease60. In uncomplicated DD, recent 
evidence indicates the presence of dysbiosis whose principal fea-
ture is the depletion of bacterial species with anti-inflammatory 
activity61 that likely favors mucosal inflammation. Recently, in 
rodent models, it has also been reported that aging-associated 
microbiota promotes inflammation and intestinal permeability 
and increases pro-inflammatory cytokines in the blood62, an 
aspect that could be relevant in DD, whose prevalence increases 
with age. Diet has an essential role in the maintenance of a 
healthy microbiota, and several types of food have been reported 
to be risk factors for AD likely through changes in microbiota 
composition. Among them, unprocessed red meat affects 
cecal microbial composition and metabolites63 and aggravates 
experimental-induced colitis, an effect counteracted by the 
co-consumption of resistant starch, which is considered a type 
of fiber that provides the benefits of both insoluble and soluble 
fibers64, an observation that could fit with the protective effects of 
a high-fiber intake in AD prevention. Fiber is known to possess 
anti-inflammatory effects and to have a eubiotic impact on gut 
microbiota65,66.
The presence of mucosal inflammation is still a matter of 
debate, except for DD-associated segmental colitis, a very rare 
mucosal inflammation sparing the rectum67. Evidence derived 
from studies carried out on small numbers of patients supports 
Figure 1. Pathogenic unifying hypothesis. CYT, cytokines; LPS, lipopolysaccharide; ROS, reactive oxygen species.
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its presence. A strong positive correlation has been reported 
between activated CD68+/CD163+ macrophages and complicated 
sigmoid diverticulitis68, and an increase in the mast cell popula-
tion has been found in the mucosal peridiverticular region61. iNOS 
and NO release, which are expressed in an inflammatory context, 
are increased in colonic mucosa, presenting a progressive trend 
from diverticulosis to SUDD with previous diverticulitis69. 
Similarly, higher chronic inflammatory infiltrates and inflam-
matory cytokine expression have been found in the affected 
tissue in patients after severe versus non-severe diverticulitis25. 
However, the presence of mucosal inflammation has not been 
confirmed by a recent study carried out in a large number (255) 
of patients, at least neither in diverticulosis nor in SUDD70. 
The absence of clear evidence regarding the efficacy of mesala-
zine in preventing both AD and its recurrence fits with these 
discrepancies.
The confirmation of an inflammatory mucosal context has 
several implications. Firstly, inflamed microenvironment in the 
gut drives bacterial dysbiosis71, favoring a vicious cycle between 
dysbiosis-driven inflammation and inflammation-driven dysbio-
sis. Secondly, mucosal inflammation and dysbiosis might lead to 
dysmotility72, another pathogenic factor associated with DD.
Dysmotility is present in both uncomplicated and complicated 
DD owing to a summation of different abnormalities73. Increased 
motility index and abnormal propulsive activity have been 
reported in patients with DD74, and enhanced contractile 
response has been observed in DD muscle strips, with upregula-
tion of substance P and muscarinic M3 receptors75–77. In addition, 
specific abnormalities in longitudinal muscle relaxation and 
contents of neural nitric oxide and elastin have been reported78, 
confirming old observations of elastosis confined to the longi-
tudinal muscle layer with subsequent shortening of the teniae 
coli79. A remodeling of the neuromuscular apparatus occurs 
in complicated DD, consisting of a muscular hypertrophy and 
architecture disarrangement with reduced content in density of 
myocytes and contractile myofilaments80, an enteric neuropa-
thy with hypoganglionosis, an imbalance in neurotransmitters, a 
deficiency of glial neurotrophic factors coupled to a nerve fiber 
remodeling81–83, and an increase in collagen deposition in the 
colon wall84. An increase in collagen expression has been observed 
in human colonic circular and longitudinal smooth muscle cells 
from complicated DD, parallel to a switch from a contractile 
to a synthetic phenotype85. Of note is also that young patients 
with AD present an altered ratio between collagen subtypes with 
respect to female and older patients86.
As a whole, these alterations increase the rigidity and thickening 
of the colonic wall and subsequent loss of tensile strength that 
could squeeze the diverticulum orifice, favoring ischemia and 
stasis. The presence of a hypercontractile status may offer an 
explanation for the protective role reported for calcium chan-
nel blockers and conversely the increased risk of AD associated 
with opioids and NSAIDs. Opioids inhibit propulsive motility 
patterns87, while NSAIDs, by inhibition of COX enzymes, reduce 
prostaglandin-driven vasodilatation and muscle relaxation88. 
Of note, however, is that most of the available data have been 
obtained from surgical specimens of chronic stages of DD, 
and then it remains to be established whether neuromuscular 
alterations correspond to a primary or secondary post-inflammatory 
event. If the enteric neuromuscular pathology reflects a pri-
mary event, this could lead to disturbed intestinal motility 
patterns, increased intraluminal pressure, and ultimately to the 
formation of diverticula and relative inflammation, whereas if 
inflammatory events are considered as the driving force for the 
neuromuscular abnormalities, these changes would arise as 
secondary lesions resembling an associated pathology.
The scarce efficacy of the actual medical treatments aimed to 
counteract luminal pathogenetic factors, however, suggests 
that some other extra-luminal factors likely contribute to DD 
complex pathogenesis. Up to now, minor attention has been 
given to the alterations of the extra-luminal microenvironment. 
Microbiota-driven mucosal inflammation can favor the transloca-
tion of luminal bacteria from the diverticula wall to the perivisceral 
area with potential activation of receptors of the innate immune 
system, Toll-like receptors (TLRs), that can drive an inflamma-
tory response in the surrounding tissues. In Crohn’s disease, the 
creeping fat surrounding the affected area was found to contrib-
ute to the overall inflammatory response89 and to be associated 
with a structuring/fistulizing course of disease90. Similarly, 
surrounding visceral fat has been hypothesized to play a patho-
genic role in complicated DD91. In this context, the clinically 
significant link that has recently been reported between visceral 
fat and the severity of the presentation of diverticulitis is of 
interest, with visceral to subcutaneous ratio likely representing 
a predictive value of more complicated disease92, in accordance 
with obesity as a risk factor for AD.
Bacterial translocation from the diverticula wall to the periv-
isceral area can also activate TLRs expressed on human 
colonic muscular cells93. LPS binding to TLR4 is capable of 
triggering persistent and long-term oxidation-driven phenotypic 
myogenic cellular alterations94, which are conceivably asso-
ciated with a smooth muscle cell ‘shift’ toward the synthetic 
phenotype95, resulting in a functional impairment of human 
colonic smooth muscle cells. Massive intramuscular fibrosis of 
both muscle layers has been described in DD96 and recently 
fibrosis, not predictable on endoscopic mucosal biopsies, has 
also been detected in DD submucosa97. Of note is that maxi-
mum colonic wall thickness is one of the factors used to predict 
recurrent diverticulitis98. This observed fibrotic trend could be 
influenced by NSAIDs, a known risk factor for AD and recur-
rences, that cause an enteropathy characterized by multiple 
short-segment strictures99. Part of the NSAID-induced dam-
age in the gastrointestinal tract is caused by an uncoupling 
of mitochondrial oxidative phosphorylation that favors oxidative 
stress100. Likewise, the protective effect of statins could be 
related to their possible anti-fibrotic effects101. The involvement 
of peridiverticular tissues might then contribute to the decrease 
in compliance leading to stiffer tissue that is more suscepti-
ble to tears, especially under conditions of increased luminal 
pressures favored by muscular hypertrophy.
Acute diverticulitis management
AD clinical classification and risk stratification is based on 
CT, which is able to offer a more comprehensive evaluation of 
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uncomplicated and complicated forms, and severity and man-
agement are graded with the use of modified Hinchey’s criteria6. 
More recently, a detailed classification of AD was proposed by 
German guidelines based on CT and clinical laboratory criteria7 
(Table 2). Among AD, roughly two-thirds of patients present with 
uncomplicated diverticulitis102.
In this setting, an important role might be provided by abdomi-
nal US, which, in the hands of experienced physicians, can be 
used as a sensitive and specific diagnostic tool7–10. A multicenter 
study evaluating the accuracy of US compared with CT in 
unselected patients referred for acute abdominal pain to the 
emergency department showed that CT has a higher sensitivity 
compared to US in detecting AD (81% versus 61%; p=0.048)103. 
Currently, however, a strategy for providing CT after negative 
or inconclusive US has been proposed7,9,10.
There has been considerable focus over the past few decades on 
a conservative treatment strategy based on the administration of 
systemic antibiotics as well as on surgery either electively or in 
an emergency setting.
More than five years ago, Chabok et al. published the first 
prospective RCT in this area, the AVOD trial, showing that 
antibiotic treatment in patients with uncomplicated diverticulitis 
(without CT signs of abscess, fistula, or free air) neither accel-
erates recovery nor prevents complication or recurrences104. 
The most recent multicenter RCT of observational versus 
systemic antibiotic treatment (DIABOLO trial: amoxicillin plus 
clavulanic acid 1.2 g four times daily intravenously for at least 
48 hours, after which the route was switched to oral admin-
istration of 625 mg three times daily) for a first episode of 
CT-proven uncomplicated AD (Hinchey stages 1a and 1b) showed 
that observational treatment without antibiotics did not pro-
long recovery and can be considered appropriate in patients with 
uncomplicated diverticulitis19. However, even if no significant 
differences between Hinchey stages 1a and 1b diverticulitis 
were found, it should be noted that the vast majority of patients 
included had a diagnosis of Hinchey stage 1a AD (90.1% in the 
observational and 94% in the antibiotic-treated group) with only 
a small percentage of patients with Hinchey stage 1b diverticu-
litis. Although these results suggested that antibiotics may not 
be necessary in patients with Hinchey stage 1b diverticulitis, 
currently no strong evidence to treat these patients without 
antibiotics is available, and more data need to be collected. 
In fact, a recent systematic review of national and interna-
tional guidelines recommended treating small abscesses with 
antibiotics18. Moreover, only short-term results in omitting 
antibiotics were reported by both cited RCTs (AVOD and 
DIABOLO trials). More recently, the long-term effects of 
Table 2. Acute diverticulitis management and classification according to modified Hinchey and German 
Society Gastroenterology classifications.
Modified Hinchey 
Classification 
German society 
Gastroenterology 
Classification
Management
1a  
Confined pericolonic phlegmon 
and associated inflammation 
without an organized fluid 
collection
1a  
No peridiverticulitis
 
Consider outpatients management
Not routine use of systemic antibiotic*
1b  
Pericolonic phlegmon
1b  
Pericolonic abscess less than  
4 cm in size, adjacent to the 
area of diverticulitis
2a  
Concealed perforation abscess 
≤1cm
 
Hospitalization
Bowel rest, parenteral fluids
Systemic antibiotic
2  
Pelvic or inter-loop abscess, or 
abscess larger than 4 cm
2b  
Paracolic or mesocolic abscess 
>1cm
 
Hospitalization
Bowel rest, parenteral fluids
Systemic antibiotic
Consider Ultrasonography- or CT-guided 
drainage
Consider surgery 
2c  
Free perforation
 
Hospitalization
Bowel rest, parenteral fluids, 
Systemic antibiotic
Consider laparoscopic lavage/surgery 
3  
Purulent peritonitis
2c1  
Purulent peritonitis
4  
Fecal peritonitis
2c2  
Fecal peritonitis
*except for immunocompromised patients and severe comorbidities
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omitting antibiotics in uncomplicated AD were assessed after 
24 months’ follow-up of the DIABOLO trial105. In the obser-
vational group, even if no significant differences were found in 
terms of recurrent diverticulitis and sigmoid resection, a higher 
number of elective resections was reported. Accordingly, the 
most recent European7–10,106,107 and American108 guidelines 
suggest the non-routine use of systemic antibiotics in patients 
with uncomplicated AD (Table 2). The need of hospitalization 
has been reconsidered as well, and a recent systematic review 
supported the safety, efficacy, and economic efficiency of an 
outpatient-based treatment approach109.
The management of complicated AD depends on its severity 
and complexity, requiring hospitalization, bowel rest, parenteral 
fluids, and, in selected cases, surgery. Antibiotic therapy is part 
of the management of complicated diverticulitis, and recent 
European guidelines7–10,106,107 are in accordance in recommending 
the use of broad-spectrum antibiotics (Table 2).
How to best treat complicated AD with surgery has been under 
debate and subject to notable changes recently. In particular, 
the number of episodes is not the only indication for surgery in 
patients with recurring diverticulitis: the individual case and 
course is also taken into account. A recent open-label ran-
domized multicenter trial (DIRECT trial) randomized 109 
patients after an episode of AD to receive surgical treatment or 
conservative management110. After a brief follow-up of 6 months, 
elective sigmoidectomy resulted in a better quality of life (assessed 
by many specific questionnaires) compared to conservative man-
agement. These results, even if innovative, might be affected 
by the heterogeneity of patients included (both patients with 
recurrent diverticulitis and patients with persistent abdominal 
complaints). In this setting, clinicians should carefully assess 
the relationship between symptoms and colonic diverticula 
differentiating abdominal complaints from irritable bowel 
syndrome, whose prevalence might increase after an episode of 
AD24.
Currently, the decision to perform an elective resection after one 
or more episodes of AD should be undertaken on a case-by-case 
basis, taking into account risk factors, complications, age, and 
severity of episodes as well as the patient’s personal circumstances 
and comorbidities (i.e. immunosuppressed patients)111,112.
Actually, the possible recognition of clinical or biochemical 
parameters that could be used to identify patients who progress 
from uncomplicated to complicated AD and to monitor the 
potential development of complications requiring immediate 
surgical intervention are matters of debate. Procalcitonin113 and 
neutrophil count and white cell to lymphocyte ratio114 have been 
proposed as accurate markers to differentiate complicated from 
uncomplicated diverticulitis, and higher levels of calprotectin, 
an inflammatory colonic mucosal marker, tend to be associated 
with more severe AD25. Clinical predictors of early recurrences 
up to 6 months after a first episode of AD appear to be high 
C-reactive protein (CRP) levels115, the presence of systemic 
inflammatory response syndrome, high pain score, and regular 
steroid or immunomodulator use116. For now, the proper timing 
of surgically treating AD remains undetermined, with surgical 
resection probably being reserved for patients with severe 
recurrences. Abscess formation should be treated by ultra-
sonography- or CT guided drainage while patients with signs of 
free perforation should undergo immediate surgery. Because of 
advancements in interventional technologies and laparoscopic 
treatment methods, surgical therapy is primarily aimed towards 
the control of emergency situations and avoidance of Hartmann’s 
procedures112.
Medical strategies for acute diverticulitis prevention
Treatment protocols in DD, especially for AD prevention, have 
been recently summarized117. In AD prevention, epidemiological 
studies suggested that people consuming the highest quantity 
of fiber had a 41% lower risk of developing DD (0.59, 0.46 to 
0.78; p<0.001) in comparison with those consuming less fiber46, 
with the reduced risk being strongest for cereal and fruit fiber39. 
This is in accordance with many national guidelines7–10,106,107 
supporting their use.
Regarding rifaximin, recent evidence118 confirms that short 
monthly cycles of rifaximin with fiber supplementation may 
reduce the risk of AD occurrence, even if the number needed to 
treat (NNT) to prevent an episode of AD in one year was 57119. 
Despite the high NNT, Polish107 and Italian9,10 guidelines 
recommend the use of rifaximin associated with fiber intake. 
Data regarding the use of rifaximin for the secondary prevention 
of AD are weak, and recent guidelines did not agree with each 
other, with some for8–10 and others against7,108 its use. The most 
recent open RCT evaluated the efficacy of one-year intermit-
tent rifaximin plus fiber to prevent AD recurrence120. After 
randomization, the underpowered number of patients included 
caused a study switch from evidence gathering to proof of 
concept. However, the authors reported that rifaximin was more 
effective compared to fiber alone in the secondary prevention 
of AD, with recurrence occurring in 10.4% versus 19.3% of 
patients, respectively (p=0.033).
Data regarding the use of mesalazine are inconclusive and more 
studies are needed, even if some positive results emerged for 
AD primary prevention121. Recently, the role of mesalazine 
in the secondary prevention of AD has been investigated by 
several RCTs122,123 that showed that mesalazine is not signifi-
cantly superior to placebo in preventing AD recurrence. A recent 
Cochrane systematic review124 confirmed the uncertain role 
for mesalazine and its effects on AD recurrence, and a similar 
conclusion was drawn by a recent meta-analysis125.
Conclusion: possible tailored therapeutic strategies
In the last few years, the main goal that has been achieved in 
the management of AD is that uncomplicated AD can, to a 
larger extent, be managed on an outpatient basis with no or little 
supportive therapy, a strategy that will certainly impact on the 
health-related costs of this disease. A second achievement, 
one that needs more controlled studies, is the finding that one 
primary preventive intervention in AD is diet, specifically an 
adequate intake of fiber. The preferred type of fiber still needs 
to be elucidated considering that a high content in a FODMAP 
diet could cause an increase in colonic gas and fluids due to 
fermentation126.
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Some other topics, mainly concerning AD recurrences, remain 
topics of debate. There is also a need of robust well-designed 
placebo-controlled RCTs that take into account the clinical 
history of the patient in order to achieve clearer evidence.
Because of an ascertained multifactorial pathogenesis of 
uncomplicated and complicated AD, it is likely that a single 
‘causa prima’ will be not identifiable. In turn, it would be useful to 
stratify patients in order to separate those who could respond to 
lifestyle modifications from those with more aggressive disease 
who could be treated better with surgery. It is possible that 
besides age-dependent alterations, different pathogenic pheno-
types might characterize more aggressive and complicated DD, 
such as those observed in younger people. A better stratification 
or a longer and more careful observation of the natural history of 
the diverticulosis versus diverticulitis process could be helpful to 
verify this hypothesis. It must be kept in mind that the actual 
therapeutic strategies (anti-inflammatory drugs, non-absorbable 
antibiotics, and probiotics), targeted towards luminal alterations, 
more easily demonstrated by the use of endoscopic samples, 
showed unsatisfactory efficacy in primary and secondary 
prevention. A better understanding of the different possible 
factors involved will be of great help in the planning of different 
possible therapeutic strategies, such as the use of nutraceuticals, 
and in pursuing tailored therapeutic algorithm strategies.
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